Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04242186 · ClinicalTrials.gov registry record · NA
Nursing Home Prevention of Injury in Dementia (NH PRIDE)
A NA study, sponsored by Hebrew SeniorLife.
- Completed
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT04242186 is a NA study that has completed, run by Hebrew SeniorLife. The registered enrollment target is 140 participants.
The verdict
NCT04242186, a NA study, has completed, sponsored by Hebrew SeniorLife.
- COMPLETED
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a consistent approach to prevent falls with injury in nursing home (NH) residents. A centralized Injury Liaison Service (ILS) will be developed and tested in four nursing home facilities (two in the Durham, North Carolina area and two in the Boston, Massachusetts area). The ILS will combine successful elements of a Fracture Liaison Service (FLS) and video telehealth staff education (ECHO) models with the goal of decreasing injurious falls in nursing home residents. The ILS Program has four main components: 1. Automated identification of NH residents at high risk for falls with injury 2. Recommendations by the ILS nurse to manage medications, including deprescribing medications associated with falls and a prescription for osteoporosis medications 3. Video telehealth sessions to educate staff 4. Shared decision making with residents and/or families. The central hypothesis of this study is that the ILS model will reduce injurious falls by changing care delivery in two areas: deprescribing psychoactive and cardiometabolic drugs to reduce falls, and increasing osteoporosis treatment to prevent injury in the setting of a fall. Qualitative interviews will be conducted with nursing home staff to gain a better understanding of effective and non-effective injury prevention strategies. Information from these interviews will be incorporated into the study design. Outcome measures will focus on acceptability, demand, practicality, and feasibility of the program, as well as safety.
Interventions
- OTHER Injury Liaison Service
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2019-10-30 |
| Est. Completion | 2022-05-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04242186
The ClinicalTrials.gov registry entry for NCT04242186 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hebrew SeniorLife, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Injury Liaison Service is the first listed.
NCT04242186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04242186 about?
NCT04242186 is a clinical study titled "Nursing Home Prevention of Injury in Dementia (NH PRIDE)". The purpose of this study is to develop a consistent approach to prevent falls with injury in nursing home (NH) residents. A centralized Injury Liaison Service (ILS) will be developed and tested in four nursing home facilities (two in the Durham, North Carolina area and two in the Boston, Massachuse...
What is the current status of trial NCT04242186?
This trial is currently completed. It is a NA study. The enrollment target is 140 participants. The study started on 2019-10-30. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT04242186?
The interventions under investigation include: Injury Liaison Service (OTHER).
Who is sponsoring clinical trial NCT04242186?
This trial is sponsored by Hebrew SeniorLife, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.